Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.
BACKGROUND: Renal transplant patients often have severe bone and mineral deficiencies. While the clinical effects of immunosuppressive agents like calcineurin inhibitors (CIs) and sirolimus on bone turnover are unclear, bisphosphonates are effective in bone recovery in these patients. Gender is sign...
Main Authors: | Wen-Hung Huang, Shen-Yang Lee, Cheng-Hao Weng, Ping-Chin Lai |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3502459?pdf=render |
Similar Items
-
Oral squamous cancer cell-bone interactions and resistance to alendronate (Fosamax) drug therapy in 3D-live bone-microenvironment
by: Hwang, Melody
Published: (2018) -
Impact of clinically used alendronate (Fosamax) on cancer-bone metastasis and bone biology revealed by novel 3D-bone organ model systems
by: Alasmari, Abeer Saeed
Published: (2018) -
Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study
by: Zhang Y, et al.
Published: (2017-07-01) -
Use of alendronate in the therapy of osteoporosis
by: O. B. Ershova
Published: (2020-01-01) -
The Effect of Alendronate in Male Osteoporosis
by: Özlem El, et al.
Published: (2004-12-01)